Beyond the Big Three: Microsoft, Hippocratic AI, and OpenEvidence (and Why They Matter More for FQHCs)

Microsoft Dragon Copilot: safety-net-aware pricing (one of two as of May 2026)

When this article first published, Microsoft Dragon Copilot was the only major-lab pricing structure that explicitly recognized safety-net economics. As of May 20, 2026, that's no longer accurate — Suki AI now also offers FQHC-discount pricing (see next section). But Microsoft's Rural Health Resiliency Program remains the largest-scale and most operationally mature safety-net pricing program in the major-lab category.

Microsoft launched Dragon Copilot at HIMSS 2025 — the productized successor to Nuance DAX (which Microsoft acquired in 2021).

One year later at HIMSS 2026, the product serves 100,000+ clinicians daily across 9 countries with support for 58 languages. That's the broadest multilingual scribe coverage on the market.

The meaningful HIMSS 2026 announcement for FQHCs was the Microsoft Rural Health Resiliency Program. Eligible rural hospitals get 60% off Dragon Copilot, plus readiness assessments and consulting via Pivot Point Consulting.

The eligibility criteria appear to track HRSA rural designations and Critical Access Hospital status. Many California FQHCs have rural sites in Mendocino, Lake, Trinity, Humboldt, Del Norte, Modoc, Lassen, Plumas, Sierra, Inyo, Mono, Tuolumne, Calaveras, and Mariposa counties — exactly the geography the program targets. If your FQHC operates in any of those service areas, the discount conversation is worth having.

Dragon Copilot's clinical leadership is also among the strongest of the major labs.

Dr. David Rhew MD serves as Microsoft's Global Chief Medical Officer (former CMO at Samsung Electronics America, internal medicine background); Joe Petro leads Health & Life Sciences engineering (former Nuance CTO); Dr. Hadas Bitran PhD leads health AI research.

The Nuance heritage matters — Dragon Copilot inherits a clinical voice technology lineage going back two decades.

Suki AI: the fourth vendor on FQHC ambient scribing

On May 20, 2026, Suki AI announced a coordinated push into community health centers — ~12 FQHC customers, FQHC-specific discount pricing (the second major-lab vendor after Microsoft to offer it explicitly), and a 9x first-year ROI claim from the pilot cohort.

Suki's clinical AI product family — Suki Assistant (ambient note generation), Suki Speech (voice-controlled EHR navigation), Suki Coder (computer-assisted coding) — was already widely deployed at academic medical centers and large multi-specialty groups. The May 2026 announcement is the first time Suki has packaged itself for the CHC economics specifically.

Suki's positioning matters because it changes the FQHC ambient-scribe map from a 3-vendor consideration (Abridge / Sunoh.ai / Microsoft Dragon Copilot) to a 4-vendor consideration. The 9x ROI claim is vendor-sourced and should be pressure-tested — but the underlying mechanism (FQHC-discount pricing + higher per-encounter documentation efficiency at safety-net visit volumes) is plausibly sound.

The 5-year eClinicalWorks + Sunoh.ai cohort is now the FQHC reference benchmark to compare Suki against — Family Health Centers Louisville is running 76 providers at 95% Sunoh.ai coverage in a 40% LEP panel.

If your FQHC is currently evaluating vendor scribes, Suki should now be on the RFP list. The cleanest test: get vendor demos from Abridge, Sunoh.ai (via eClinicalWorks if you're on that EHR), Microsoft Dragon Copilot (if you qualify for Rural Health Resiliency), and Suki. Pressure-test all four on multilingual quality, EHR integration depth, and total cost over 36 months. The competition is finally good for FQHCs.

Hippocratic AI: the strongest physician founding bench in healthcare AI

Hippocratic AI raised $126M at a $3.5B valuation in November 2025 (Series C, led by Avenir Growth, with CapitalG, General Catalyst, a16z, Kleiner Perkins, Premji Invest). Total raised: $404M.

The company makes patient-facing AI agents — 'AI nurses' that conduct outreach, monitor chronic disease, follow up post-discharge, and support medication adherence. The product is called Polaris.

What makes Hippocratic AI different from the Big Three: the founding team includes two practicing-physician co-founders — Dr. Meenesh Bhimani MD and Dr. Kim Parikh MD — alongside CEO Munjal Shah, AI researcher Subhabrata Mukherjee PhD, and engineer Vishal Parikh.

Anthropic has zero publicly named MDs. OpenAI has Nate Gross MD. Google has DeSalvo MD + Howell MD. Hippocratic AI has the deepest physician founding bench of any AI lab on the comparison list — clinical safety is built into the founding DNA.

The investor list reinforces this: Universal Health Services, Cincinnati Children's Hospital Medical Center, and WellSpan Health are all on the cap table — health systems as investors is unusual and signals deep clinical co-design.

In 15 months since first commercial deployment, Hippocratic AI has 50+ enterprise customers across 6 countries: Cleveland Clinic (US + Abu Dhabi), Northwestern Medicine, Ochsner Health, Moffitt Cancer Center, University Hospitals, Guy's & St Thomas' NHS Trust (UK), Sanford Health, OhioHealth, Memorial Hermann, VNS Health (NY), Sheba Medical Center (Israel), Fraser Health (Canada), and more.

The VNS Health deployment is the closest analog to FQHC community-based care — Visiting Nurse Service of NY does exactly the kind of post-acute, home-based, chronic-disease-monitoring work that FQHCs increasingly need to scale. If patient-facing AI is on your 2026-2027 roadmap, Hippocratic AI's clinical credibility and VNS Health reference make it the most defensible enterprise pitch.

OpenEvidence: already inside your FQHC at scale

OpenEvidence reached a $12 billion valuation in January 2026 on a $250M raise led by Thrive Capital and DST Global. Doubled from $6B in October 2025. Total raised: $700M in less than a year. Investors include Sequoia, Mayo Clinic, Google's venture arm, Nvidia, Kleiner Perkins, Craft Ventures.

The numbers are extraordinary. 40% of US physicians use OpenEvidence daily. 757,000+ verified doctors signed up. 20+ million clinical consultations per month (up from 3M/month a year earlier — 6-7x growth). 10,000+ hospitals and medical centers. $100M+ in annual recurring revenue.

CEO Daniel Nadler PhD previously founded Kensho Technologies (sold to S&P Global for $550M).

What this means for FQHCs: you don't need to evaluate whether to deploy OpenEvidence. Your physicians already use it. Some fraction of your FQHC clinical workforce — likely between 20% and 50% depending on specialty mix — is already opening OpenEvidence on their phones during clinical encounters.

The product is FREE for verified physicians, NPs, and PAs, so there's no procurement step to track and no billing trail to follow.

The strategic question is governance. OpenEvidence's value proposition is citation-grounded answers — every clinical response cites peer-reviewed sources, and Mayo Clinic is both an investor and a content partner. That's clinically defensible, but FQHC leadership needs visibility: which clinicians are using it, for what queries, with what frequency.

An institutional account / dashboard would let your CMO support and govern that adoption rather than treating it as shadow IT. Worth a direct conversation with OpenEvidence's enterprise team.

How these three change the FQHC AI strategy in 2026

The original AI lab gap argument — 23 enterprise launch customers, 0 FQHCs — applies to the frontier labs (Anthropic, OpenAI, Google). It's a structural observation about where the major foundation-model players are putting partnership effort. That gap is real and worth pushing on through NACHC or OCHIN consortium-broker conversations.

But the broader 7-lab landscape shows a more nuanced picture. Microsoft has built a pricing structure that explicitly serves rural / safety-net providers. Hippocratic AI has built a clinical bench depth (2 MD co-founders + health systems on the cap table) that the frontier labs don't match. OpenEvidence has built a physician-trust franchise that already reaches your clinicians whether or not you have a procurement relationship.

For FQHC executives building 2026 AI strategy, this means three new questions:

• Does your FQHC qualify for the Microsoft Rural Health Resiliency Program 60% Dragon Copilot discount? Pivot Point Consulting is the operational partner; they handle the eligibility assessment.
• If patient-facing AI (chronic disease monitoring, post-discharge follow-up, medication adherence) is on your roadmap, can Hippocratic AI's VNS Health deployment scale to a community-health context? Their cap table includes 3 health systems — that's a clinical credibility ceiling worth using.
• How many of your physicians are already using OpenEvidence? Survey them. Then escalate to OpenEvidence's enterprise team about an institutional dashboard — Mayo Clinic content licensing should extend to FQHC tier without academic-medical-center pricing.

CA compliance overlay (May 2026)

Holland & Knight's May 2026 review identified California AB 3030 and SB 1120 as the two active compliance triggers any CA FQHC has to factor in when deploying ANY of the vendors above. Both statutes are now in effect for the 2026 plan year.

AB 3030 (mandatory patient disclosure + explicit consent before AI is used in care) directly affects how you deploy Microsoft Dragon Copilot ambient scribing — patients must be told the AI is listening before it listens, and must consent. The Spanish-language version of the disclosure script matters for the multilingual panels Dragon Copilot's 58-language coverage is built for.

For Hippocratic AI's Polaris patient-facing voice agents, AB 3030 applies at every patient-AI touchpoint: the introduction, the consent capture, the data-use language, and the human-handoff path. The product is designed for this — but your CA compliance officer needs to verify the specific scripts before launch.

SB 1120 (a human clinician must make the final medical-necessity call on any utilization-management decision that touches AI) affects OpenEvidence indirectly. The product itself is clinician-decision-support — the SB 1120 language is structured around UM decisions made by payers, not bedside clinical reasoning.

But if your FQHC uses OpenEvidence to support prior-auth letters or appeals (which Penny and other RCM tools are increasingly designed for), the SB 1120 documentation requirement becomes material. The cleanest position: have a human clinician sign every AI-influenced UM document, and capture that signature in the workflow.

Net: none of these vendors are blocked in CA, but each requires a deployment-specific compliance overlay. Build the scripts and audit logs before launch — not after the first OCR complaint.

What we'll watch in Q3 2026

Three things to track between now and the next major healthcare-AI conference cycle (Epic UGM 2026 in August; HLTH in October):

• Whether Microsoft expands the Rural Health Resiliency Program to include FQHCs explicitly — currently it's framed around rural hospitals, but the eligibility criteria likely overlap meaningfully with HRSA-designated FQHC sites.
• Whether Hippocratic AI announces an FQHC partnership or NACHC consortium pilot — VNS Health was the first community-based deployment; community health centers are the obvious next vector.
• Whether OpenEvidence launches an FQHC-tier enterprise plan — at 40% US physician adoption, the FQHC physician share is non-trivial. Monetizing that institutional layer is a natural next move.
• And the broader question: which lab makes the first explicit FQHC partnership announcement? It will reset the baseline expectations across the entire sector. If you have a board-level relationship with NACHC or OCHIN leadership, this is a worth-mentioning conversation.